FI891689A0 - Som antiinflammatoriska och antidegenerativa medel anvaendbara nya substituerade azetidinoner. - Google Patents

Som antiinflammatoriska och antidegenerativa medel anvaendbara nya substituerade azetidinoner.

Info

Publication number
FI891689A0
FI891689A0 FI891689A FI891689A FI891689A0 FI 891689 A0 FI891689 A0 FI 891689A0 FI 891689 A FI891689 A FI 891689A FI 891689 A FI891689 A FI 891689A FI 891689 A0 FI891689 A0 FI 891689A0
Authority
FI
Finland
Prior art keywords
azetidinoner
antiinflammatoriska
antidegenerativa
substituerade
anvaendbara
Prior art date
Application number
FI891689A
Other languages
English (en)
Other versions
FI891689A (fi
Inventor
Shrenik K Shah
Paul E Finke
James B Doherty
William Hagmann
Peter L Barker
Conrad P Dorn
Raymond A Firestone
Original Assignee
Merck & Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck & Co Inc filed Critical Merck & Co Inc
Publication of FI891689A0 publication Critical patent/FI891689A0/fi
Publication of FI891689A publication Critical patent/FI891689A/fi

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D231/00Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D205/00Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
    • C07D205/02Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
    • C07D205/06Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D205/08Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with one oxygen atom directly attached in position 2, e.g. beta-lactams
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D233/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D249/00Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/081,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/08Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing alicyclic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
FI891689A 1988-04-11 1989-04-10 Som antiinflammatoriska och antidegenerativa medel anvaendbara nya substituerade azetidinoner. FI891689A (fi)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US17968888A 1988-04-11 1988-04-11

Publications (2)

Publication Number Publication Date
FI891689A0 true FI891689A0 (fi) 1989-04-10
FI891689A FI891689A (fi) 1989-10-12

Family

ID=22657566

Family Applications (1)

Application Number Title Priority Date Filing Date
FI891689A FI891689A (fi) 1988-04-11 1989-04-10 Som antiinflammatoriska och antidegenerativa medel anvaendbara nya substituerade azetidinoner.

Country Status (21)

Country Link
EP (1) EP0337549B1 (fi)
JP (1) JP2736113B2 (fi)
KR (1) KR930008223B1 (fi)
CN (1) CN1037144A (fi)
AT (1) ATE128704T1 (fi)
AU (1) AU621865B2 (fi)
CA (1) CA1337990C (fi)
DE (1) DE68924439T2 (fi)
DK (1) DK169329B1 (fi)
ES (1) ES2079373T3 (fi)
FI (1) FI891689A (fi)
GR (1) GR3017656T3 (fi)
HU (1) HUT50761A (fi)
IE (1) IE891140L (fi)
IL (1) IL89835A0 (fi)
LV (1) LV11459B (fi)
NO (1) NO891470L (fi)
NZ (1) NZ228600A (fi)
PT (1) PT90222B (fi)
YU (1) YU71489A (fi)
ZA (1) ZA892549B (fi)

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5229510A (en) * 1983-12-01 1993-07-20 Merck & Co., Inc. β-lactams useful in determining the amount of elastase in a clinical sample
US5229381A (en) * 1983-12-01 1993-07-20 Merck & Co., Inc. Substituted azetidinones as anti-inflammatory and antidegenerative agents
WO1992018488A1 (fr) * 1991-04-10 1992-10-29 Japan Tobacco Inc. Nouveau derive d'oxazinone
IL99658A0 (en) * 1990-10-15 1992-08-18 Merck & Co Inc Substituted azetidinones and pharmaceutical compositions containing them
GB9103654D0 (en) * 1991-02-21 1991-04-10 Merck Sharp & Dohme Chemical process
US5100880A (en) * 1991-03-20 1992-03-31 Merck & Co., Inc. Novel betalactam elastase inhibitors containing phosphorous acid derivatives at the 4-position of the 2-azetidinone
US5104862A (en) * 1991-03-20 1992-04-14 Merck & Co., Inc. Bethalactam elastase inhibitors containing phosphorous acid derivatives at the 4-position of the 2-azetidinone
US5348953A (en) * 1991-06-25 1994-09-20 Merck & Co., Inc. Substituted azetidinones as anti-inflammatory and antidegenerative agents
WO1993000332A1 (en) * 1991-06-25 1993-01-07 Merck & Co., Inc. Substituted azetidinones as anti-inflammatory and antidegenerative agents
US5688785A (en) * 1991-07-23 1997-11-18 Schering Corporation Substituted azetidinone compounds useful as hypocholesterolemic agents
EP0524595A1 (en) * 1991-07-23 1993-01-27 Schering Corporation Substituted beta-lactam compounds useful as hypocholesterolemic agents and processes for the preparation thereof
US5688787A (en) * 1991-07-23 1997-11-18 Schering Corporation Substituted β-lactam compounds useful as hypochlesterolemic agents and processes for the preparation thereof
US5229267A (en) * 1991-08-26 1993-07-20 Merck & Co., Inc. Assay for evaluating inhibition of PMN elastase by N-substituted azetidinones
US5276139A (en) * 1991-08-26 1994-01-04 Merck & Co., Inc. Haptens useful in evaluating inhibition of PNN elastase by N-substituted azetidinones
EP0529719A1 (en) * 1991-08-26 1993-03-03 Merck & Co. Inc. Assay for evaluating inhibition of PMN elastase by N-Substituted Azetidinones
US5274080A (en) * 1991-08-26 1993-12-28 Merck & Co., Inc. Monospecific antibodies useful in evaluating inhibition of polymorphonuclear leukocyte elastase by N-substituted azetidinones
US5149838A (en) * 1991-09-20 1992-09-22 Merck & Co., Inc. Intermediates for substituted azetidinones useful as anti-inflammatory and antidegenerative agents
GB2266527A (en) * 1992-03-17 1993-11-03 Merck & Co Inc Substituted azetidinones useful in the treatment of leukemia
US5250676A (en) * 1992-03-23 1993-10-05 University Of Notre Dame Du Lac Process for the preparation of 3-substituted-2-azetidinones
MY128261A (en) * 1992-10-27 2007-01-31 Merck Sharp & Dohme New substituted azetidinones as anti-inflammatory and antidegenerative agents
WO1994010143A1 (en) * 1992-10-27 1994-05-11 Merck & Co., Inc. New substituted azetidinones as anti-inflammatory and antidegenerative agents
US5591737A (en) * 1992-12-17 1997-01-07 Merck & Co., Inc. Substituted azetidinones as anti-inflammatory and antidegenerative agents
AU5802894A (en) * 1992-12-17 1994-07-04 Merck & Co., Inc. New substituted azetidinones as anti-inflammatory and antidegenerative agents
LT3595B (en) 1993-01-21 1995-12-27 Schering Corp Spirocycloalkyl-substituted azetidinones useful as hypocholesterolemic agents
GB9314350D0 (en) * 1993-07-12 1993-08-25 Zeneca Ltd Armide derivatives
US5420010A (en) * 1993-07-30 1995-05-30 Merck & Co., Inc. Assay for evaluating inhibition of polymorphonuclear leukocyte elastase by N-substituted azetidinones
US5631365A (en) 1993-09-21 1997-05-20 Schering Corporation Hydroxy-substituted azetidinone compounds useful as hypocholesterolemic agents
US5403952A (en) * 1993-10-08 1995-04-04 Merck & Co., Inc. Substituted cyclic derivatives as novel antidegenerative agents
JPH09510212A (ja) * 1994-03-11 1997-10-14 メルク エンド カンパニー インコーポレーテッド 肺疾患を処置するための組成物
US5627176A (en) * 1994-03-25 1997-05-06 Schering Corporation Substituted azetidinone compounds useful as hypocholesterolemic agents
US5624920A (en) * 1994-11-18 1997-04-29 Schering Corporation Sulfur-substituted azetidinone compounds useful as hypocholesterolemic agents
US5633246A (en) * 1994-11-18 1997-05-27 Schering Corporation Sulfur-substituted azetidinone compounds useful as hypocholesterolemic agents
US5656624A (en) * 1994-12-21 1997-08-12 Schering Corporation 4-[(heterocycloalkyl or heteroaromatic)-substituted phenyl]-2-azetidinones useful as hypolipidemic agents
WO1996029307A1 (fr) * 1995-03-23 1996-09-26 Japan Tobacco Inc. Composes de diphenylmethyle-azetidinone et inhibiteur d'elastase
US5747485A (en) * 1995-04-13 1998-05-05 Merck & Co., Inc. Substituted azetidiones as anti-inflammatory and antidegenerative agents
US5523233A (en) * 1995-05-03 1996-06-04 Merck & Co., Inc. Enzymatic hydrolysis of 3,3-diethyl-4-[(4-carboxy)phenoxy]-2-azetidinone esters
PL324240A1 (en) * 1995-07-01 1998-05-11 Smithkline Beecham Plc Derivatives of azetidinone for treating atherosclerosis
WO1997013750A1 (en) * 1995-10-09 1997-04-17 Chiroscience Limited Azetidinones and their therapeutic use as cytokine inhibitors
JP2000502079A (ja) * 1995-12-08 2000-02-22 スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー アテローム性動脈硬化症の治療のための単環β―ラクタム誘導体
BR9709196A (pt) * 1996-04-26 1999-05-25 Smithkline Beecham Plc Derivados de azetidinona para o tratamento de aterosclerose
US5756470A (en) * 1996-10-29 1998-05-26 Schering Corporation Sugar-substituted 2-azetidinones useful as hypocholesterolemic agents
US6903075B1 (en) 1997-05-29 2005-06-07 Merck & Co., Inc. Heterocyclic amide compounds as cell adhesion inhibitors
WO1999018073A1 (en) * 1997-10-07 1999-04-15 Boehringer Ingelheim (Canada) Ltd. Azetidinone derivatives for the treatment of hcmv infections
CA2301543C (en) * 1997-10-07 2005-05-17 Boehringer Ingelheim (Canada) Ltd. Azetidinone derivatives for the treatment of hcmv infections
WO1999018071A1 (en) * 1997-10-07 1999-04-15 Boehringer Ingelheim (Canada) Ltd. Azetidinone derivatives for the treatment of hcmv infections
WO1999064395A1 (en) * 1998-06-11 1999-12-16 Merck & Co., Inc. Heterocyclic amide compounds as cell adhesion inhibitors
US6335324B1 (en) 1998-06-25 2002-01-01 Bristol-Myers Squibb Co. Beta lactam compounds and their use as inhibitors of tryptase
WO2000005204A1 (fr) * 1998-07-23 2000-02-03 Shionogi & Co., Ltd. COMPOSES DE β-LACTAME MONOCYCLIQUES ET INHIBITEURS DE LA CHYMASE LES RENFERMANT
AU4343500A (en) 1999-04-16 2000-11-02 Schering Corporation Use of azetidinone compounds
IL157552A0 (en) 2001-03-28 2004-03-28 Schering Corp Enantioselective synthesis of azetidinone intermediate compounds
US7056906B2 (en) 2001-09-21 2006-06-06 Schering Corporation Combinations of hormone replacement therapy composition(s) and sterol absorption inhibitor(s) and treatments for vascular conditions in post-menopausal women
ES2311806T3 (es) 2003-03-07 2009-02-16 Schering Corporation Compuesto de azetidinona sustituidos, fornulaciones y usos de los mismos para el tratamiento de hipercolesterolemia.
EP1601669B1 (en) 2003-03-07 2008-12-24 Schering Corporation Substituted azetidinone compounds, formulations and uses thereof for the treatment of hypercholesterolemia
US8440819B2 (en) 2008-02-22 2013-05-14 Allergan, Inc. Therapeutic substituted beta-lactams

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4680391A (en) * 1983-12-01 1987-07-14 Merck & Co., Inc. Substituted azetidinones as anti-inflammatory and antidegenerative agents

Also Published As

Publication number Publication date
FI891689A (fi) 1989-10-12
AU621865B2 (en) 1992-03-26
DE68924439T2 (de) 1996-05-09
KR930008223B1 (ko) 1993-08-27
NO891470L (no) 1989-10-12
ES2079373T3 (es) 1996-01-16
ZA892549B (en) 1989-11-29
NZ228600A (en) 1992-02-25
PT90222B (pt) 1994-07-29
YU71489A (en) 1991-10-31
EP0337549B1 (en) 1995-10-04
AU3263089A (en) 1989-10-12
NO891470D0 (no) 1989-04-10
JPH026471A (ja) 1990-01-10
DK169329B1 (da) 1994-10-10
IE891140L (en) 1989-10-11
DK170589D0 (da) 1989-04-10
CA1337990C (en) 1996-01-23
LV11459A (lv) 1996-08-20
LV11459B (en) 1996-12-20
GR3017656T3 (en) 1996-01-31
IL89835A0 (en) 1989-12-15
KR900016121A (ko) 1990-11-12
ATE128704T1 (de) 1995-10-15
JP2736113B2 (ja) 1998-04-02
DK170589A (da) 1989-10-12
DE68924439D1 (de) 1995-11-09
EP0337549A1 (en) 1989-10-18
CN1037144A (zh) 1989-11-15
PT90222A (pt) 1989-11-10
HUT50761A (en) 1990-03-28

Similar Documents

Publication Publication Date Title
FI891689A (fi) Som antiinflammatoriska och antidegenerativa medel anvaendbara nya substituerade azetidinoner.
ES553821A0 (es) Un procedimiento para la preparacion de nuevas azetidinonas sustituidas.
FI874839A (fi) Nya substituerade kefalosporinsulfoner anvaendbara som antiinflammatoriska och antidegenerativa medel.
FI871495A0 (fi) Nya lipolytiska enzymer och deras anvaendning i detergentkompositioner.
DK0393936T3 (da) 3-substituerede 2-oxindolderivater som antiinflammatoriske midler
FI931163A0 (fi) Kompositioner innehaollande kombinationer av ytaktiva medel och baernstensyraacyleringsmedelderivat eller hydroxiaromatiska aemnen och anvaendning av dessa
MX9101574A (es) Nuevas azetidinonas substituidas como agentes anti-inflamatorios y antidegenerativos
FI875411A (fi) Foerfarande och anordning foer inriktning och laengsriktad foerskjutning av avrundade burkars kanter i foerhaollande till en svetsanordning.
FI935117A (fi) Nya antiinflammatoriska isoxazoliner
FI953106A (fi) Difuoripentapeptidijohdannaiset anti-inflammatorisina aineina
FI883135A (fi) Homocyklostatin och cyklostatin innehaollande polypeptider som antihypertensiva medel.
DE3575563D1 (de) Lichtvernetzbare zusammensetzungen.
GR880100196A (el) Υποκατεστημενα 1,3-διοξολαν-και 1,3-διοξαν-παραγωγα,μεθοδοι για την παρασκευη τους και η χρηση τους
FI860138A (fi) Nya alkalimetallaluminium -dialkyldihydrider och deras loesningar i aromatiska kolvaeten.
KR940011228U (ko) 고속/고안정 앰프
FI915019A0 (fi) Nya 11-metylenestr-15-ener och kompositioner innehaollande desamma foer anvaendning som preventivmedel.
FI933146A0 (fi) Karbocykliska och heterocykliska fusionerade dihydropyridiner som kardioskyddande medel och nya heterocykliska och karbocykliska fusioneradedihydropyridiner, foerfarande foer deras framstaellning och mellanprodukter foer deras framstaellning
FI922516A0 (fi) Nya antikroppar och deras anvaendning i diagnostiska metoder.

Legal Events

Date Code Title Description
FA Application withdrawn

Owner name: MERCK & CO., INC.